The Real Drivers of GLP-1 Growth

The episode outlines five drivers of GLP-1 therapy adoption: oral formulations, Medicare access, lower out-of-pocket costs, global expansion, and therapeutic innovation beyond weight loss. It projects a $190B base-case global market by 2035, with 12% of 1.3B eligible patients treated, and highlights a potential 1-2% reduction in U.S. calorie consumption.

Investors get a structured, data-backed framework for forecasting the $190B+ GLP-1 market, grounded in access, cost trends, and clinical expansion.

1. 01Only 6% of eligible U.S. obesity patients currently use GLP-1 therapies, indicating significant growth runway.
2. 02Oral GLP-1s are driving expansion, with nearly 80% of users being new to the category.
3. 03Medicare access and falling out-of-pocket costs (down to $120/month) are accelerating adoption, with employer coverage expected to reach 65% by 2027.